FOLR1 and ovarian carcinoma: To this end, we demonstrated successful targeting of PAtrace to the FRα receptor on SKOV3 ovarian cancer cells in both in vitro and in vivo settings and observed increased PAtrace CE of targeted FRα-PAtrace in SKOV3 tumors relative to non-targeted RG-16-PAtrace.